Immuno-interferometric sensor for the detection of influenza A nucleoprotein.

Influenza A virus, both seasonal and pandemic, has the potential to cause rampant devastating disease around the world. The most relied upon methods of viral detection require days, skilled workers, and laboratory settings to complete properly. Here, we report two methods for the detection of the nucleoprotein from inactivated influenza A (IFA-NP), a patented polymer-protein antibody orientation immuno-method, termed ALYNGSA, and a newly fabricated optical label-free Fabry-Perot interferometric immunosensor. The ALYGNSA assay for IFA-NP had a level of detection below 5 microg/mL of inactivated virus sample. The label-free detection through Fabry-Perot interferometry with the ALYGNSA orientation yielded an improved sensitivity to 1 microg/mL over the fluorescence sandwich assay alone. Characterization of the detection surface by fluorescence microscopy and non-contact AFM corroborated interferometry results. The resulting label-free detection method has the prospective for adaptation into a portable multi-chip sensor capable of real-time in situ detection of influenza A virus.

Novel fluoroimmunoassay for ovarian cancer biomarker CA-125.

Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.5 U/ml compared to that of a commercial CA-125 enzyme-linked immunosorbent assay (15 U/ml) This tenfold lower level of detection of the ALYGNSA CA-125 assay should permit better identification and monitoring of ovarian cancer.

Antibody orientation enhanced by selective polymer-protein noncovalent interactions.

A unique interaction has been found between protein G' (a truncated recombinant bacterial "alphabet" protein which aligns by noncovalent attachment to the antibody stem) and poly(methyl methacrylate), a thermoplastic polymer substrate, which can be easily fabricated using high-rate processes. Significantly improved orientation efficiency with traditional passive adsorption for this system (termed ALYGNSA) has been achieved as compared to the same assay performed on a polystyrene substrate with protein G'. Results were consistent with an average alignment of 80% of the human immunoglobulin G capture antibody which translated into a 30% to 50% improved alignment over an array of industry standards tested. Laser scanning confocal microscopy confirmed the immunological results. Studies of additional poly(methyl methacrylate) polymer derivatives and protein biolinker (A and AG) combinations have been conducted and have revealed different degrees of antibody alignment. These findings may lead to additional novel noncovalent methods of antibody orientation and greater sensitivity in immunological assays.